Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
5 studies found for:    CEBPA
Show Display Options
Rank Status Study
1 Completed Studying Biomarkers in Cell Samples From Patients With Acute Myeloid Leukemia
Condition: Leukemia
Interventions: Genetic: RNA analysis;   Genetic: gene expression analysis;   Genetic: mutation analysis;   Genetic: protein expression analysis;   Other: fluorescence activated cell sorting;   Other: laboratory biomarker analysis
2 Completed S0106B Studying Bone Marrow Samples From Women With Acute Myeloid Leukemia
Condition: Leukemia
Interventions: Genetic: gene expression analysis;   Other: flow cytometry;   Other: fluorescence activated cell sorting;   Other: laboratory biomarker analysis;   Other: medical chart review
3 Completed A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old
Condition: Acute Myeloid Leukemia
Interventions: Drug: conventional chemotherapy (AraC + Daunorubicin),;   Drug: Mylotarg associated with conventional chemotherapy (AraC + Daunorubicin),
4 Active, not recruiting Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: lenalidomide;   Drug: cytarabine;   Drug: idarubicin hydrochloride;   Other: pharmacological study;   Other: laboratory biomarker analysis
5 Recruiting PETHEMA-LMA10: Treatment of Acute Myeloblastic Leukemia (AML) in Patients Less Than or Equal to 65 Years
Condition: Acute Myeloblastic Leukemia
Interventions: Drug: IDARUBICINE;   Drug: ARA-C

Indicates status has not been verified in more than two years